Metropolis Healthcare Limited (METROPOLIS) Financial Results — Revenue ₹1,646 Cr

Revenue: ₹1,646 CrNet Profit: ₹194 Cr

📢 Key Event
Metropolis Healthcare reports 23% YoY revenue growth and 140 bps EBITDA margin expansion in Q4 FY26

🔄 What Changed
23% YoY revenue growth, 140 bps EBITDA margin improvement, 25% digital revenue contribution, 13.7% organic growth

🔮 What's Next
27-28% EBITDA margin target over next 3 years

💡 Investor Takeaway
The company is driving sustainable growth through digital adoption, lab consolidation, and productivity gains, targeting higher margins and long-term expansion without near-term price increases.

Metropolis Healthcare reported Q4 FY26 revenue of [amount context mismatch] crores (+23% YoY) and full-year revenue of ₹1,646 crores (+23.6% YoY), with EBITDA margins of 25.4% (Q4) and 24.4% (FY26), reflecting margin expansion of 140 basis points driven by organic growth, digital adoption (25% of revenue), and lab consolidation. The company achieved 13.7% organic revenue growth for the full year, supported by 7-8% patient volume growth, 20% growth in TruHealth and Specialty segments, and 14% YoY lab productivity improvement. Management highlighted sustainable growth through network expansion (100 mini hubs planned), digital transformation, and productivity gains, targeting 27-28% EBITDA margins over the next three years. No near-term price hikes are planned, but future adjustments may occur based on market conditions.